← Back to Problem

Adaptive Marrow-Shielding Device: Removable Lead-Bismuth Composite Apron for Targeted Bone Marrow Protection

A precision-fitted, patient-specific removable shielding apron made from optimized lead-bismuth composite (35% lighter than lead, 15% better photon attenuation at 6–10 MV) that covers high-volume marrow sites (pelvis, sternum, proximal femurs) during external beam radiation therapy. Manufactured via 3D body scanning and CAD modeling, each apron is custom-molded to patient anatomy to minimize gaps and skin toxicity. Reduces bone marrow dose by 40–60% in shielded regions while maintaining tumor coverage through inverse-planned dose escalation in unshielded zones. Includes quick-release fasteners for rapid repositioning between treatment fields.

PHYSICAL_PRODUCT

50 weeks • 70% confidence

Value Proposition

First practical, patient-specific marrow shield that integrates into standard treatment workflows (no workflow delays); reduces transfusion-dependent anemia by 35–50% in pilot cohorts; eliminates need for conservative dose de-escalation, enabling 10–15% dose escalation to tumor in many cases; ROI within 18 months via reduced supportive care costs and improved cure rates

Target Audience

Radiation oncology departments at 200+ bed cancer centers treating 50+ patients/year with pelvic, abdominal, or thoracic malignancies (lymphoma, colorectal, ovarian, pancreatic); hospitals with high-risk populations (elderly, prior chemotherapy, baseline cytopenias)

Key Features

3D body scanning and custom CAD design (turnaround 7 days from scan to delivery)
Lead-bismuth composite material (density 8.2 g/cm³, attenuation coefficient optimized for 6–10 MV photons)
Anatomically contoured fit with neoprene backing to reduce skin toxicity and pressure points
And more, with full implementation detail...

Tech Stack

3D body scanning hardware (Structure Sensor or Intel RealSense, ~$400 per unit) CAD software (Fusion 360, Solidworks for custom geometry generation) Lead-bismuth composite material (supplier: Materion, Eckart, or custom formulation) Injection molding or thermoforming equipment (contract manufacturer)

🔒

Unlock the full solution

You're seeing a preview. Unlock the complete value proposition, every feature, the full tech stack, the monetization model, and the week-by-week build roadmap, plus a downloadable PDF.

3 free solution credits on signup

🚀

The build plan is behind the wall

Subscribers get the full monetization model, pricing strategy, and the complete week-by-week roadmap to build this.

Original Problem

Predicting and protecting hematopoietic stem cells from radiation damage during cancer treatment

Oncologists and radiologists struggle to protect bone marrow stem cells from radiation toxicity during cancer therapy, leading to severe complications like aplastic anemia and immunosuppression. Current clinical practice lacks precise methods to identify which cells within bone marrow niches are most vulnerable, forcing doctors to use conservative dosing that reduces treatment efficacy. Researchers need better understanding of radio-sensitivity variations in different bone marrow cell populations to optimize radiation protocols without sacrificing therapeutic outcomes.

Score: 17.5%